Hybrid Compounds as Multitarget Directed Anticancer Agents

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Discovery

Background:

• Cancer treatment faces challenges from multifactorial origins and multidrug resistance (MDR) in chemotherapy.
• Existing single-target anticancer drugs often exhibit limitations like poor solubility and adverse effects.
• There is a critical need for novel, more potent anticancer agents capable of selective cancer cell elimination.

Purpose of the Study:

• To review recent studies on hybrid compounds as multitargeted anticancer agents.
• To highlight the advantages of hybrid drugs in overcoming cancer treatment challenges.
• To emphasize the potential of hybrid compounds in advancing cancer therapy.

Main Methods:

• Focus on hybrid compounds synthesized by conjugating two or more bioactive moieties into a single molecule.
• Compilation and analysis of data from recent studies utilizing these novel hybrid anticancer drugs.
• Review of the design, synthesis, and clinical trial outcomes of hybrid anticancer agents.

Main Results:

• Hybrid compounds, by targeting multiple pathways, demonstrate enhanced efficacy and potency against cancer cells.
• These agents effectively overcome common limitations of single-target drugs, including multidrug resistance (MDR).
• Recent studies confirm the significant potential of hybrid compounds as effective novel anticancer drugs.

Conclusions:

• Hybrid compounds represent a promising strategy for developing next-generation anticancer therapeutics.
• Continued research, design, synthesis, and clinical trials of hybrid compounds are essential for future cancer treatment advancements.
• Multitargeted hybrid drugs offer a viable approach to combat complex cancers and improve patient outcomes.